9.43
price up icon1.62%   0.15
 
loading
Organon Co stock is traded at $9.43, with a volume of 3.55M. It is up +1.62% in the last 24 hours and down -3.97% over the past month. Organon & Co is a science-based pharmaceutical company that develops and delivers health solutions through a portfolio of prescription therapies within women's health, biosimilars, and established brands. The Company's operations include the following product portfolio: Women's health, Biosimilars and Established medicines. Geographically, it derives a majority of its revenue from Europe and Canada followed by the United States and then Asia Pacific and Japan. The company generates the majority of its revenue from the Established Brands product portfolio.
See More
Previous Close:
$9.28
Open:
$9.39
24h Volume:
3.55M
Relative Volume:
0.83
Market Cap:
$2.45B
Revenue:
$6.29B
Net Income/Loss:
$750.00M
P/E Ratio:
3.2743
EPS:
2.88
Net Cash Flow:
$586.00M
1W Performance:
-0.11%
1M Performance:
-3.97%
6M Performance:
-39.12%
1Y Performance:
-54.86%
1-Day Range:
Value
$9.33
$9.64
1-Week Range:
Value
$9.15
$9.64
52-Week Range:
Value
$8.01
$23.10

Organon Co Stock (OGN) Company Profile

Name
Name
Organon Co
Name
Phone
551-430-6000
Name
Address
30 HUDSON STREET, JERSEY CITY
Name
Employee
10,000
Name
Twitter
Name
Next Earnings Date
2024-10-31
Name
Latest SEC Filings
Name
OGN's Discussions on Twitter

Compare OGN with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
OGN
Organon Co
9.43 2.41B 6.29B 750.00M 586.00M 2.88
Drug Manufacturers - General icon
LLY
Lilly Eli Co
711.68 625.77B 53.26B 13.80B -50.20M 15.30
Drug Manufacturers - General icon
JNJ
Johnson Johnson
179.29 424.47B 90.62B 22.66B 18.18B 9.35
Drug Manufacturers - General icon
ABBV
Abbvie Inc
210.60 364.92B 58.33B 3.73B 18.24B 2.10
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
126.98 240.07B 53.40B 13.68B 16.89B 6.9231
Drug Manufacturers - General icon
MRK
Merck Co Inc
87.37 210.36B 63.43B 16.42B 14.72B 6.49

Organon Co Stock (OGN) Upgrades & Downgrades

Date Action Analyst Rating Change
May-02-25 Downgrade Evercore ISI Outperform → In-line
Sep-06-24 Downgrade JP Morgan Neutral → Underweight
Nov-03-23 Downgrade Goldman Buy → Neutral
Sep-21-23 Initiated Barclays Overweight
Mar-16-23 Initiated Raymond James Outperform
Oct-14-22 Downgrade BofA Securities Neutral → Underperform
Sep-06-22 Upgrade Piper Sandler Neutral → Overweight
Aug-05-22 Downgrade BofA Securities Buy → Neutral
Apr-27-22 Initiated Goldman Buy
Apr-06-22 Resumed Morgan Stanley Equal-Weight
Oct-07-21 Initiated Piper Sandler Neutral
Sep-01-21 Initiated BofA Securities Buy
Jul-22-21 Initiated Citigroup Buy
Jun-15-21 Initiated JP Morgan Neutral
Jun-11-21 Initiated Morgan Stanley Equal-Weight
Jun-10-21 Initiated Evercore ISI Outperform
View All

Organon Co Stock (OGN) Latest News

pulisher
Aug 19, 2025

Henlius And Organon Sued In US Over Plans To Market Perjeta Biosimilar - insights.citeline.com

Aug 19, 2025
pulisher
Aug 18, 2025

Does Organon's Raised 2025 Guidance Signal a Turning Point for OGN Investors? - simplywall.st

Aug 18, 2025
pulisher
Aug 16, 2025

Kahn Brothers' Q2 2025 13F Filing: Alphabet, Comcast, and Organon Highlights - AInvest

Aug 16, 2025
pulisher
Aug 16, 2025

Organon in charts: Women's Health revenue up ~3% Y/Y in Q2 - MSN

Aug 16, 2025
pulisher
Aug 15, 2025

Roche Sues Organon in First Case Over Biosimilar Copy of Perjeta - Bloomberg Law News

Aug 15, 2025
pulisher
Aug 15, 2025

There May Be Some Bright Spots In Organon's (NYSE:OGN) Earnings - Yahoo Finance

Aug 15, 2025
pulisher
Aug 14, 2025

Organon & Co. (OGN) Stock Price, News & Analysis - MarketBeat

Aug 14, 2025
pulisher
Aug 14, 2025

Daré Bioscience Posts Narrower Q2 Loss - The Motley Fool

Aug 14, 2025
pulisher
Aug 14, 2025

OGN’s Market Whiplash: -52.64% YTD Decline, -4.30% Plunge in 30 Days - investchronicle.com

Aug 14, 2025
pulisher
Aug 14, 2025

Bullish Organon Insiders Loaded Up On US$651.6k Of Stock - 富途牛牛

Aug 14, 2025
pulisher
Aug 14, 2025

Organon & Co.'s Q2 2025 Earnings Call: Unraveling Key Contradictions in Capital Allocation, Nexplanon Growth, and Financial Forecasts - AInvest

Aug 14, 2025
pulisher
Aug 14, 2025

LPL Financial LLC Has $4.87 Million Holdings in Organon & Co. (NYSE:OGN) - Defense World

Aug 14, 2025
pulisher
Aug 13, 2025

NYSE: OGN Lawsuit Alert: Investors who lost money with Organon & Co. (NYSE: OGN) shares should contact the Shareholders Foundation - The Malaysian Reserve

Aug 13, 2025
pulisher
Aug 13, 2025

Ex-Dividend Reminder: Cencora, Organon and Esquire Financial Holdings - Nasdaq

Aug 13, 2025
pulisher
Aug 13, 2025

5 Must-Read Analyst Questions From Organon’s Q2 Earnings Call - Yahoo Finance

Aug 13, 2025
pulisher
Aug 13, 2025

OGN Q2 Deep Dive: Flat Sales, Margin Pressure, and Strategic Shifts Highlight Quarter - Yahoo Finance

Aug 13, 2025
pulisher
Aug 12, 2025

Organon's Valuation: Discounted Due to Structural Challenges - AInvest

Aug 12, 2025
pulisher
Aug 12, 2025

Organon: Valuation Discount Offset By Structural Headwinds (NYSE:OGN) - Seeking Alpha

Aug 12, 2025
pulisher
Aug 12, 2025

Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know - MSN

Aug 12, 2025
pulisher
Aug 11, 2025

Natixis Advisors LLC Has $778,000 Holdings in Organon & Co. (NYSE:OGN) - Defense World

Aug 11, 2025
pulisher
Aug 10, 2025

Organon & Co. (OGN): Assessing Dividend Sustainability and Valuation Amid Earnings Pressures and Strategic Catalysts - AInvest

Aug 10, 2025
pulisher
Aug 10, 2025

Read This Before Considering Organon & Co. (NYSE:OGN) For Its Upcoming US$0.02 Dividend - uk.finance.yahoo.com

Aug 10, 2025
pulisher
Aug 08, 2025

Organon & Co. (OGN) Reports Q2 2025 Results - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Organon Q2 Preview: What to expect? - MSN

Aug 08, 2025
pulisher
Aug 08, 2025

Organon & Co. (NYSE:OGN) Given Average Recommendation of “Moderate Buy” by Brokerages - Defense World

Aug 08, 2025
pulisher
Aug 07, 2025

Organon & Co. Reports Q2 2025 Earnings, Raises Full-Year Guidance - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Organon & Co. (NYSE:OGN) Second-Quarter Results: Here's What Analysts Are Forecasting For This Year - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Organon & Co. Reports Q2 2025 Financial Results - The Globe and Mail

Aug 07, 2025
pulisher
Aug 06, 2025

Organon & Co. Earnings Call: Resilience Amid Challenges - The Globe and Mail

Aug 06, 2025
pulisher
Aug 06, 2025

Organon (OGN) Fiscal Q2 Revenue Beats 1% - AOL.com

Aug 06, 2025
pulisher
Aug 06, 2025

Organon & Co. (OGN) Slashes 13.13% on Disappointing Earnings - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Organon Q2 Earnings: It May Be Time To Desert This Sinking Ship (Downgrade) (NYSE:OGN) - Seeking Alpha

Aug 06, 2025
pulisher
Aug 06, 2025

Endometriosis Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine Biosciences - The Globe and Mail

Aug 06, 2025
pulisher
Aug 06, 2025

Organon & Co. SEC 10-Q Report - TradingView

Aug 06, 2025
pulisher
Aug 06, 2025

Organon & Co. (NYSE:OGN) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 06, 2025
pulisher
Aug 06, 2025

Organon jumps despite Q2 revenue dip as revised outlook exceeds consensus - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Organon Reports Results for the Second Quarter Ended June 30, 2025 - BioSpace

Aug 06, 2025
pulisher
Aug 06, 2025

ORGANON SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co.OGN - Discover 361

Aug 06, 2025
pulisher
Aug 06, 2025

Organon & Co. shares rise 1.67% premarket after beating Q2 revenue expectations and raising FY guidance. - AInvest

Aug 06, 2025
pulisher
Aug 06, 2025

Organon & Co (OGN) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Growth By GuruFocus - Investing.com Canada

Aug 06, 2025
pulisher
Aug 05, 2025

Organon: Q2 Earnings Snapshot - Norwalk Hour

Aug 05, 2025
pulisher
Aug 05, 2025

Organon raises 2025 revenue guidance by $100M amid Vtama ramp and debt reduction focus - MSN

Aug 05, 2025
pulisher
Aug 05, 2025

Organon & Co To Go Ex-Dividend On August 15th, 2025 With 0.02 USD Dividend Per Share - 富途牛牛

Aug 05, 2025
pulisher
Aug 05, 2025

Organon reports Q2 adjusted EPS $1.00, consensus 94c - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

Organon raises FY25 revenue view to $6.28B-$6.38B from $6.13B-$6.33B - TipRanks

Aug 05, 2025
pulisher
Aug 05, 2025

OGN Shares Plunge: Lawsuit Drives Market Shock - StocksToTrade

Aug 05, 2025
pulisher
Aug 05, 2025

Organon & Co. 2025 Q2ResultsEarnings Call Presentation (NYSE:OGN) - Seeking Alpha

Aug 05, 2025
pulisher
Aug 05, 2025

Earnings call transcript: Organon Q2 2025 beats EPS expectations, stock volatile - Investing.com

Aug 05, 2025
pulisher
Aug 05, 2025

Organon Becomes Oversold - Nasdaq

Aug 05, 2025
pulisher
Aug 05, 2025

Organon (OGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates - Yahoo Finance

Aug 05, 2025
pulisher
Aug 05, 2025

Organon & Co. Reports Strong Q2 Earnings, Surpassing ExpectationsNews and Statistics - IndexBox

Aug 05, 2025

Organon Co Stock (OGN) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Organon Co Stock (OGN) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
COX CARRIE SMITH
Director
May 14 '25
Buy
8.07
12,469
100,591
12,469
Falcione Aaron
Chief Human Resources Officer
May 07 '25
Buy
8.77
5,500
48,235
62,974
Weaver Kirke
Gen. Counsel & Corp. Secy.
May 06 '25
Buy
9.21
8,045
74,054
52,489
Karp Daniel
Executive VP, Corp. Dev.
May 06 '25
Buy
8.24
3,500
28,828
46,669
WALSH MATTHEW M
Chief Financial Officer
May 05 '25
Buy
8.82
11,400
100,548
144,484
Ali Kevin
Chief Executive Officer
May 05 '25
Buy
8.80
34,000
299,370
282,731
Falcione Aaron
Chief Human Resources Officer
Mar 31 '25
Option Exercise
0.00
18,732
0
59,237
Karp Daniel
Executive VP, Corp. Dev.
Mar 31 '25
Option Exercise
0.00
34,677
0
44,515
Stahler Rachel A
Chief Information Officer
Mar 31 '25
Option Exercise
0.00
18,334
0
78,994
WALSH MATTHEW M
Chief Financial Officer
Mar 31 '25
Option Exercise
0.00
34,870
0
136,903
drug_manufacturers_general SNY
$51.35
price up icon 1.46%
$114.77
price down icon 1.18%
drug_manufacturers_general PFE
$25.88
price up icon 0.54%
$293.72
price down icon 0.69%
drug_manufacturers_general NVO
$56.98
price up icon 2.76%
drug_manufacturers_general MRK
$87.37
price up icon 1.50%
Cap:     |  Volume (24h):